Androgen Effects on the Reproductive Neuroendocrine Axis

Open to females ages 18-35

All

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Aged 18-35

   Transgender/Non-binary Group - Initiators

4. Plan to initiate testosterone therapy
5. History of regular menstrual cycles (every 24-35 days) at baseline, before beginning TRT

Transgender/Non-binary Group - Discontinuers 4. Plan to discontinue testosterone therapy 5. History of regular menstrual cycles (every 24-35 days) before beginning TRT

Cisgender Female Group 4. Having regular menstrual cycles (every 24-35 days)

All

1. Pregnant
2. Incarcerated
3. Known cognitive impairment or institutionalized
4. Hemoglobin less than 11 gm/dl at screening evaluation
5. Weight less than 110 pounds
6. BMI <18 or >35
7. Current endocrine disease- including untreated thyroid abnormalities, pituitary or adrenal disease, polycystic ovary syndrome, or androgen producing tumor
8. Current or recent pregnancy within two months of study enrollment
9. Current or recent breast feeding within two months of study enrollment
10. Diabetes, or renal, liver, or heart disease
11. History of oophorectomy or hysterectomy
12. History of radiation or surgery involving brain structures

13. Currently taking any medications that may affect their reproductive hormones, such as contraceptive medications, androgens, estrogens, progestins, GnRH antagonists, GnRH agonists, insulinomimetics, and metformin.

    For TRT Initiation Group and Cisgender Female group:

14. History of prior testosterone therapy